GlassScriptPhysician profile
Jason John Madey
NPI 1245466937
$1,283.97
in general payments reported to CMS, 2019-2025
26 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $94.70 · 2021: $32.90 · 2022: $193 · 2023: $249 · 2024: $233 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.94 | 2022-2025 | |
| Ceribell, INC. | $181.25 | 2025 | Pocket Eeg Device |
| Biogen, INC. | $150.90 | 2022-2025 | Leqembi |
| Astrazeneca Pharmaceuticals LP | $101.33 | 2023-2024 | Andexxa |
| Sunovion Pharmaceuticals INC. | $91.95 | 2019-2020 | |
| Kyowa Kirin, INC. | $87.10 | 2024 | Nourianz |
| Amgen INC. | $42.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.21 | 2025 | Hyqvia |
| Ucb, INC. | $40.10 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $38.70 | 2023 | Ultomiris |
| Pfizer INC. | $34.40 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $33.57 | 2019 | |
| Daiichi Sankyo INC. | $23.88 | 2022 | |
| Life Molecular Imaging LTD | $23.73 | 2023 | Neuraceq |
| Csl Behring | $21.46 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.62 | 2021 | |
| Endo Pharmaceuticals INC. | $18.49 | 2023 | Xiaflex |
| Glaxosmithkline, LLC. | $17.67 | 2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $17.09 | 2019 | |
| Neurelis, INC. | $16.44 | 2020 | |
| Calliditas Therapeutics US INC. | $15.84 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $15.69 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.43 | 2022 | |
| Allergan, INC. | $15.12 | 2019 | |
| Greenwich Biosciences, INC. | $14.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Madey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.